Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Anticancer Res. 2020 Apr;40(4):2089-2093. doi: 10.21873/anticanres.14167.
BACKGROUND/AIM: The outcomes of ramucirumab after lenvatinib failure for hepatocellular carcinoma (HCC) patients with alpha fetoprotein (AFP) levels of ≥400 ng/ml are unknown.
Of 12 patients treated with ramucirumab after lenvatinib failure, 10 patients were enrolled in this retrospective study.
The disease control rate of 80% at 6 weeks and the median time to progression of 3.1 months were the same by both the Response Evaluation Criteria in Solid Tumors (RECIST) and the modified RECIST. AFP reduction was seen in 5 patients at 2 weeks and in 3 patients at 6 weeks. The incidence of grade 3 adverse events was low at 10%. The albumin-bilirubin scores within 6 weeks did not worsen.
Ramucirumab might have potential therapeutic efficacy and safety in advanced HCC patients after lenvatinib failure. Further studies are needed to confirm the outcomes of ramucirumab after lenvatinib failure.
背景/目的：仑伐替尼治疗失败后甲胎蛋白（AFP）水平≥400ng/ml的肝细胞癌（HCC）患者使用雷莫芦单抗的治疗结果尚不清楚。
在仑伐替尼治疗失败后接受雷莫芦单抗治疗的 12 名患者中，有 10 名患者被纳入本回顾性研究。
6 周时的疾病控制率为 80%，根据实体瘤反应评估标准（RECIST）和改良 RECIST，中位无进展时间均为 3.1 个月。2 周时有 5 例患者 AFP 降低，6 周时有 3 例患者 AFP 降低。3 级不良事件的发生率较低，为 10%。6 周内的白蛋白-胆红素评分没有恶化。
雷莫芦单抗可能对仑伐替尼治疗失败后的晚期 HCC 患者具有潜在的治疗效果和安全性。需要进一步的研究来确认仑伐替尼治疗失败后雷莫芦单抗的疗效。
